Linagliptin and Mesenchymal Stem Cells: A Pilot Study

Completed · Phase 4

Conditions studied: Schizophrenia

In brief

The purpose of the present study is to gather pilot data on the effects of linagliptin on the concentration of the long and short forms of SDF1-α (stromal cell-derived factor alpha) in humans, and to demonstrate the feasibility of such a study in patients with psychosis in our setting.

Key facts

Study ID

NCT02442817

Run by

University of Nevada, Reno

People needed

10

Starts

2015-03-02

Expected to finish

2018-03-02

Last updated by the study team

2020-11-09

Who can join

Age: 18 and older, up to 45. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Meets DSM (Diagnostic and Statistical Manual) criteria for schizophrenia.
• Considered clinically stable, and on the same dose of antipsychotic for two weeks.
• A score no greater than 3 on the PANSS (Positive and Negative Syndrome Scale) Conceptual Disorganization item.
• Not taking any medications for diabetes, or any anti-inflammatories other than occasional aspirin or acetaminophen. Not taking Clozapine.
• Age 18-45 years.
• Can be available for regular morning appointments from 8:00 am to 10:00 am, preferably on Tuesdays, Wednesdays and Thursdays.

You may not qualify if…

• Does not meet DSM criteria for substance abuse or dependence.
• No serious current general medical condition, such as cancer, history of stroke or myocardial infarction, tuberculosis, HIV/AIDS, hemophilia, etc.

Where it is running

• University of Nevada School of Medicine — Reno, Nevada, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.